Cognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.

Grace Teiko Lowor, a Ghanaian-born biomedical engineer and researcher at the University of Florida, is at the forefront of ...

For work identifying a novel therapeutic target to improve walking after SCI, Newton Cho is the 2025 winner of the Science & PINS Prize for Neuromodulation. The prize rewards innovative research that ...

Cognito Therapeutics today announced the presentation of new findings from a study of its non-invasive Spectris neuromodulation system.

Michigan Advanced Psychiatry pioneers FDA-approved neuromodulation therapies like TMS, IV ketamine, and Spravato to treat resistant mental health conditions, offering fast, effective alternatives for ...

A Cleveland Clinic psychiatrist explains how ketamine therapy is transforming depression treatment—and why it works when ...

Understanding mental illness requires understanding psychiatric disorder causality. New brain research explores this in ...

The neuromodulation global market is expected to grow at a high single digit CAGR from 2022 to 2029 to reach $9,569.4 million by 2029 due to increasing incidence of chronic pain, increasing ...

Wavegate Corporation, a company that makes neuromodulation technology for chronic pain management, has secured $26 million in a Series A funding round led by UCEA Capital Partners Ltd. WHAT IT DOES ...

Sacral neuromodulation is used to treat refractory overactive bladder (OAB). Recent research has shown that changes in brain activity during sacral neuromodulation relate to its mechanism of ...

The current neuromodulation market has an estimated value of $5.8 billion, with over 50% of the value given by the SCS sector.